Cramer's 'Mad Money' Recap: Staying Cautious for Coming Week's Earnings
That leaves Del Frisco's, the only one among the group Cramer said can be bought. Del Frisco's owns 32 high-end steakhouses, but unlike the failed attempts of other steakhouse stocks, this one has a clean balance sheet, room to grow and is delivering same-store sales growth between 3.5% and 4%. Trading at just 13.4 times earnings with a 16% growth rate, Cramer said this stock is far too cheap.
Car vs. Car
When the company's last reported, AutoNation reported an earnings beat, only to see its shares sell off, meanwhile CarMax missed on its earnings and saw its shares rally. Cramer said that's because the tides are changing and used cars are once again expected to outsell new ones going forward, especially with some 200,000 cars damaged by Hurricane Sandy in the northeast.
Cramer said the new car market is getting more cutthroat and competitive now that dealership closings are behind the industry. Meanwhile the supply of used cars, once constrained by the recession, is finally returning to normal levels. That leaves more opportunities for CarMax, said Cramer, and potentially tougher times for AutoNation.
Then there's the growth aspect. CarMax has 110 locations but ultimately plans for 300, expanding its footprint by 10% a year. AutoNation, on the other hand, has new car franchises, which can't be built without approvals from the manufacturers.
Cramer said shares of AutoNation are also closely held, making them not trade as well as Carmax, meanwhile CarMax just announced its first share repurchase program.
So when it comes to domestic autos, Cramer said that CarMax is the way to go.
In his "Homework" segment, Cramer tied up a few loose ends. He said Omega Healthcare (OHI) may have an 8% yield but investors need to wait for more clarity on the company's reimbursement rates. Cramer said InvenSense (INVN) has seen its stock slide in recent months so he's not a fan.
Cramer was also not a fan Greenway Medical (GWAY) , with that stock trading at 37 times earnings.
Finally, Cramer issued a mea culpa for Dynavax Technologies (DVAX) , a speculative biotech that was cut in half, down 47%, after the FDA asked for more safety information on its latest offering.